Squarepoint
NBRV

Squarepoint’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

Squarepoint’s Portfolio NBRV Stock Details NBRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-6,265
Closed -$260K – 4011
2021
Q1 		$260K Buy
+6,265
New +$389K ﹤0.01% 2520
2018
Q3 		– Sell
-61
Closed -$53K – 2332
2018
Q2 		$53K Buy
+61
New +$69.9K ﹤0.01% 1688
2018
Q1 		– Sell
-64
Closed -$95K – 2346
2017
Q4 		$95K Buy
+64
New +$101K ﹤0.01% 1966

Other funds holding NBRV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
AICPI
ABG Innovation Capital Partners III Central, Hong Kong, Hong Kong $64.5K AUM 1.01% 1-Year Est. Return
VFA
Values First Advisors Gray, Tennessee $192M AUM 24.96% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

Squarepoint's NBRV Position: Q2 2021 in Review

Squarepoint sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q2 2021, closing a stake of 6,265 shares — an estimated $260K sold.

Squarepoint first reported a position in NBRV in Q4 2017 and held it in 3 quarters. The position peaked at $260K in Q1 2021. 31 funds tracked by Wall St. Rank hold NBRV as of Q2 2021.

  • Squarepoint reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q2 2021 after selling out during the quarter.
  • Squarepoint sold 6,265 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q2 2021, an estimated $260K.
  • Squarepoint first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q4 2017 and held it in 3 quarters.
  • Squarepoint's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $260K in Q1 2021.
  • 31 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q2 2021.

Based on Squarepoint's 13F filing for Q2 2021, filed 16 Aug 2021.